Menu
Search
|

Menu

Close
X

Alexion Pharmaceuticals Inc ALXN.OQ (NASDAQ Stock Exchange Global Select Market)

123.41 USD
+0.59 (+0.48%)
As of Jul 17
Previous Close 122.82
Open 122.79
Volume 537,621
3m Avg Volume 525,742
Today’s High 125.13
Today’s Low 122.75
52 Week High 141.81
52 Week Low 92.57
Shares Outstanding (mil) 223.19
Market Capitalization (mil) 31,536.07
Forward P/E 61.23
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.94 Mean rating from 17 analysts

KEY STATS

Revenue (mm, USD)
FY19
1,140
FY18
4,131
FY17
3,551
FY16
3,084
EPS (USD)
FY19
2.607
FY18
0.077
FY17
2.173
FY16
1.744
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
61.23
32.67
Price to Sales (TTM)
vs sector
9.24
7.92
Price to Book (MRQ)
vs sector
3.57
5.39
Price to Cash Flow (TTM)
vs sector
34.12
24.37
Total Debt to Equity (MRQ)
vs sector
33.48
14.56
LT Debt to Equity (MRQ)
vs sector
31.59
10.21
Return on Investment (TTM)
vs sector
4.17
14.49
Return on Equity (TTM)
vs sector
6.11
15.79

EXECUTIVE LEADERSHIP

David Brennan
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Ludwig Hantson
Chief Executive Officer, Director, Since 2017
Salary: $1,200,000.00
Bonus: --
Paul Clancy
Chief Financial Officer, Executive Vice President, Since 2017
Salary: $900,000.00
Bonus: --
Indrani Franchini
Executive Vice President, Chief Compliance Officer, Since 2017
Salary: --
Bonus: --
Ellen Chiniara
Executive Vice President, General Counsel, Corporate Secretary, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

121 Seaport Blvd
BOSTON   MA   02210-2050

Phone: +1475.2302596
Site: alexion.com/

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

SPONSORED STORIES